In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced…
featured news
The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with…
On 20 September, International Sarcoma Day, the Asociación Iker presented the cheque with the annual collection to Dr. César Serrano,…
The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
The 3rd Research Day for Patients’ Associations took place on 6 September, focusing on colorectal cancer patients. The day began…
On September 26, the second edition of the symposium “Emerging Leaders in Biomedicine” took place, hosted by the Vall d’Hebron…
For many cancer patients, clinical trials are a new opportunity for treatment, especially in cases where various therapies have been…
Presented at ESMO Congress 2024, results from the phase 1b CodeBreaK study in patients with KRAS G12C-mutated metastatic colorectal cancer…
The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as…
Advances driven by research have led to significant developments in better understanding the molecular taxonomy of cancer and therapeutic breakthroughs…
